New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
18:25 EDTALNYAlnylam introduces a new ‘Alnylam 5x15’ program – ALN-AS1
Alnylam introduces a new ‘Alnylam 5x15’ program – ALN-AS1 for the treatment of acute intermittent porphyria, an ultra-rare genetic disease caused by loss of function mutations in an enzyme in the heme biosynthesis pathway that result in acute and/or recurrent life-threatening attacks with severe abdominal pain, peripheral and autonomic neuropathy, and neuropsychiatric manifestations. In aggregate, we believe that execution on our ‘Alnylam 5x15’ programs and our ambitious goals for 2013 and beyond will enable continued advancement of RNAi therapeutics as innovative medicines for patients, resulting in value creation for our shareholders.”
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
08:10 EDTALNYAlnylam, The Medicines Co. file application to initiate Phase 1 ALN-PCSsc study
Subscribe for More Information
October 27, 2014
07:04 EDTALNYAlnylam management to meet with Deutsche Bank
Subscribe for More Information
October 21, 2014
09:48 EDTALNYShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use